IDNs’ Numerous Strategies and Tools to Manage High-Cost Drugs

Article

IDNs’ Numerous Strategies and Tools to Manage High-Cost Drugs

May 13, 2024
Authors
Topics

Welcome to the May 2024 edition of our Monthly Insight Series. This month we’re exploring the new tools IDNs have deployed to monitor high-cost drugs. This is a preview of findings from our 2024 IDN Oncology Trend Survey, coming at the end of May.

Stock image of person holding pills behind a graph

As the growth of drug expenses continues to outpace other expenses, integrated delivery networks (IDNs) are increasingly deploying sophisticated tools to monitor, manage, and influence prescribing behaviors. Our most recent 2024 IDN Oncology Trend Survey—scheduled for release at the end of this month—specifically looked at the use of high-cost drug review or committees because the majority of IDNs (~70%) use one of these mechanisms to consider both inpatient and outpatient treatments, which includes cancer drugs.

The Figure below illustrates the types and prevalence of tools IDNs with high-cost drug reviews or committees use to monitor these drugs.

  • Of the IDNs with high-cost drug reviews, over 90% deploy two or more tools to monitor and manage these drugs.
  • The most common tool was high-cost drug utilization reports, deployed by 84% of IDNs with high-cost drug reviews.
  • In addition to retrospective reports, most IDNs with high-cost drug reviews have also implemented real-time alerts or tools to manage or guide prescribing. These include electronic health record alerts notifying providers of the need for additional approvals (75%), as well as real-time drug pricing tools (58%).

 

MAI May 2024 Graph

Figure. Share of IDNs With High-Cost Drug Reviews That Deploy Various Tools (2024; N = 112) Includes only IDNs that have high-cost drug reviews (69% of IDNs), and 1% of respondents were unsure.
Source: HMP Market Access Insights 2024 IDN Oncology Trend Report.
Abbreviations: EHR, electronic health record. IDN, integrated delivery network.

 

Manufacturers should be aware of how the variety of tools IDNs deploy to manage prescribing may influence prescribing patterns, and we look forward to sharing additional insights later this month when we release our full 2024 IDN Oncology Trend report!

The Latest

Frustrated man surrounded by technology, papers, people.
Article
Oncology Clinics Frustrated With Manufacturer Engagement Tactics

Welcome to the June 2024 edition of our Monthly Insight Series! This month we’re discussing oncology clinic concerns with existing manufacturer engagement approaches, using data drawn from our 2024 Community Oncology report, coming later in June.

Ashutosh Sheth
Doctor looking at papers
Article
When Do Payer Pathways Matter?

While provider-initiated oncology clinical pathways are regaining momentum, payer pathways struggle to find a foothold in this space. Still, they can exert impact under certain conditions.

Cindy Chen
Stock image of person holding pills behind a graph
Article
IDNs’ Numerous Strategies and Tools to Manage High-Cost Drugs

Welcome to the May 2024 edition of our Monthly Insight Series. This month we’re exploring the new tools IDNs have deployed to monitor high-cost drugs. This is a preview of findings from our 2024 IDN Oncology Trend Survey, coming at the end of May.

Emma Bijesse